Interpretation of expert consensus on diagnosis and treatment of eosinophilic granulomatous polyvasculitis in 2018
- Author:
Yan-feng LIN
1
;
Ying-xiu ZHANG
1
;
Chao-li FU
1
;
Mei-shun LIN
1
;
Jia-mei CHEN
1
;
Bei-ping ZHANG
1
;
Tian-wen LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: eosinophilic granulomatous polyvasculitis; hormone; immunosuppressive agents
- From: Chinese Journal of Practical Internal Medicine 2019;39(05):437-439
- CountryChina
- Language:Chinese
- Abstract: According to the different organs involved in patients, the concept of localized Eosinophilic granulomatous polyvasculitis(EGPA) was first proposed by consensus in 2018, which provides a basis for the early diagnosis and treatment of EGPA. The prognosis of patients with EGPA is related to the initial treatment. The treatment of EGPA depends on the severity of the disease, the organs involved and whether the disease is active or not. The overall treatment plan is divided into two stages: induction remission and maintenance therapy. Induced remission therapy mainly includes hormones and/or immunosuppressive agents(e.g. cyclophosphamide). After remission, azathioprine or methotrexate is recommended for maintenance therapy. In 2015, the global consensus of EGPA diagnostic and therapeutic experts recommended that the duration of treatment should be at least 24 months after remission. In combination with the latest international progress, the first Expert Consensus on Diagnosis and Treatment of EGPA in China 2018 consensus introduced the application of Bio-Targeting drugs in EGPA.
